Analysts' Opinions Are Mixed on These Financial Stocks: Renaissancere Holdings (RNR), Baldwin Insurance Group (BWIN) and SpareBank 1 Nord-Norge (OtherSPXXF)
Analysts have been eager to weigh in on the Financial sector with new ratings on Renaissancere Holdings (RNR – Research Report), Baldwin Insurance Group (BWIN – Research Report) and SpareBank 1 Nord-Norge (SPXXF – Research Report).
Confident Investing Starts Here:
Renaissancere Holdings (RNR)
In a report issued on May 7, Michael Zaremski from BMO Capital maintained a Buy rating on Renaissancere Holdings, with a price target of $275.00. The company's shares closed last Friday at $238.99.
According to TipRanks.com, Zaremski is a 5-star analyst with an average return of 12.4% and a 71.9% success rate. Zaremski covers the Financial sector, focusing on stocks such as Skyward Specialty Insurance Group, Inc., Fidelis Insurance Holdings Ltd., and American International Group.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Renaissancere Holdings with a $282.10 average price target, a 18.2% upside from current levels. In a report issued on April 25, Morgan Stanley also upgraded the stock to Buy with a $275.00 price target.
Baldwin Insurance Group (BWIN)
BMO Capital analyst Charlie Lederer maintained a Buy rating on Baldwin Insurance Group on May 7 and set a price target of $51.00. The company's shares closed last Friday at $38.00.
According to TipRanks.com, Lederer is ranked #6781 out of 9562 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Baldwin Insurance Group with a $43.50 average price target, representing a 16.1% upside. In a report issued on May 7, William Blair also maintained a Buy rating on the stock.
SpareBank 1 Nord-Norge (SPXXF)
In a report issued on May 22, ABG Sundal Collier from ABG Sundal downgraded SpareBank 1 Nord-Norge to Sell, with a price target of NOK126.00. The company's shares closed last Thursday at $7.78, equals to its 52-week low of $7.78.
The the analyst consensus on SpareBank 1 Nord-Norge is currently a Hold rating.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
7 hours ago
- Business Insider
Analysts Offer Insights on Industrial Goods Companies: Boeing (BA) and Symbotic (SYM)
Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Boeing (BA – Research Report) and Symbotic (SYM – Research Report). Confident Investing Starts Here: Boeing (BA) In a report released today, Gavin Parsons from UBS maintained a Buy rating on Boeing, with a price target of $245.00. The company's shares closed last Tuesday at $215.73. According to Parsons is a 4-star analyst with an average return of 6.6% and a 66.3% success rate. Parsons covers the Industrial Goods sector, focusing on stocks such as L3Harris Technologies, StandardAero, Inc., and Northrop Grumman. Boeing has an analyst consensus of Strong Buy, with a price target consensus of $219.95, a 1.1% upside from current levels. In a report issued on June 4, Jefferies also maintained a Buy rating on the stock with a $250.00 price target. Craig-Hallum analyst Greg Palm assigned a Hold rating to Symbotic today. The company's shares closed last Tuesday at $28.23. Symbotic has an analyst consensus of Moderate Buy, with a price target consensus of $29.63.
Business Insider
a day ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Bio-Rad Laboratories (BIO) and Ramsay Health Care (OtherRMSYF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bio-Rad Laboratories (BIO – Research Report) and Ramsay Health Care (RMSYF – Research Report). Confident Investing Starts Here: Bio-Rad Laboratories (BIO) RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories on June 5 and set a price target of $381.00. The company's shares closed last Monday at $225.56. According to McNamara 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.5% and a 18.4% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, SOPHiA GENETICS, and Exact Sciences. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Rad Laboratories with a $316.40 average price target. In a report released today, Steven Wheen from Jarden maintained a Hold rating on Ramsay Health Care, with a price target of A$44.05. The company's shares closed last Thursday at $24.00. According to Wheen is ranked #1103 out of 9627 analysts. The word on The Street in general, suggests a Hold analyst consensus rating for Ramsay Health Care with a $25.09 average price target.
Business Insider
a day ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN) and Medtronic (MDT)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Illumina (ILMN – Research Report) and Medtronic (MDT – Research Report) with bullish sentiments. Confident Investing Starts Here: Illumina (ILMN) RBC Capital analyst Conor McNamara maintained a Buy rating on Illumina on June 5 and set a price target of $115.00. The company's shares closed last Monday at $84.98, close to its 52-week low of $79.30. According to McNamara has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.5% and a 18.4% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and SOPHiA GENETICS. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Illumina with a $107.13 average price target, which is a 28.3% upside from current levels. In a report issued on May 27, Leerink Partners also maintained a Buy rating on the stock. Medtronic (MDT) The company's shares closed last Monday at $87.45. According to Jennings is a 4-star analyst with an average return of 5.3% and a 52.7% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Establishment Labs Holdings, and Zimmer Biomet Holdings. Medtronic has an analyst consensus of Moderate Buy, with a price target consensus of $95.76, a 9.6% upside from current levels. In a report issued on May 27, Argus Research also maintained a Buy rating on the stock with a $105.00 price target.
